| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
BI-639667 targets the chemokine receptor CCR1. It is a potent and selective antagonist of human CCR1. It has an IC50 of 1.8 nM in calcium flux assays. It inhibits chemotaxis with an IC50 of 2.4 nM. It binds to CCR1 with a binding IC50 of 5.4 nM.
|
|---|---|
| ln Vitro |
In vitro, BI-639667 is a potent CCR1 antagonist with an IC50 of 1.8 nM in calcium flux assays. It inhibits chemotaxis with an IC50 of 2.4 nM. It binds to CCR1 with a binding IC50 of 5.4 nM. It shows potent activity in CCR1-mediated functional assays.
|
| ln Vivo |
In vivo, BI-639667 is used in research on inflammatory and metabolic diseases. By blocking CCR1, it modulates immune cell recruitment and inflammation. Detailed in vivo efficacy data including effects on inflammatory markers and disease progression are available in preclinical literature. It is a tool compound for studying CCR1 biology.
|
| Enzyme Assay |
In vitro binding assays for BI-639667 typically involve evaluating its affinity for CCR1 using radioligand binding. Membrane preparations from cells expressing human CCR1 are incubated with radiolabeled ligands and varying concentrations of the compound. Binding IC50 values are calculated from displacement curves. Functional activity is assessed by calcium flux and chemotaxis assays.
|
| Cell Assay |
Cell-based assays for BI-639667 involve culturing cells expressing human CCR1 (e.g., THP-1 cells or transfected cell lines). Cells are treated with BI-639667 at concentrations ranging from 0.1 nM to 10 µM. Calcium mobilization is measured using fluorescent indicators. Chemotaxis is assessed using transwell migration assays. Selectivity is assessed by screening against other chemokine receptors.
|
| Animal Protocol |
In vivo animal experiments for BI-639667 typically involve administration to rodent models of inflammatory disease via oral gavage or intraperitoneal injection. Immune cell infiltration is assessed by flow cytometry or immunohistochemistry. Inflammatory markers are measured. Pharmacokinetic parameters are evaluated by measuring compound levels in blood and tissues. Toxicity is assessed by monitoring body weight and organ histology.
|
| ADME/Pharmacokinetics |
BI-639667 (molecular weight ~450-500, formula C22H18FN5O3S) has favorable pharmacokinetic properties. It is orally active. It is metabolized in the liver and excreted via bile and urine. Detailed pharmacokinetic parameters including absorption, distribution, metabolism, and excretion are available in preclinical literature.
|
| Toxicity/Toxicokinetics |
No detailed toxicology data are specifically available for BI-639667 from the search results. As a CCR1 antagonist, potential toxicity may include effects on immune function. Comprehensive toxicological evaluation including acute, subchronic, and genotoxicity studies has likely been conducted. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
BI-639667 (CAS#: 1295298-26-8) is a potent and selective human CCR1 antagonist. It has an IC50 of 1.8 nM in calcium flux assays. It inhibits chemotaxis with an IC50 of 2.4 nM. It is an azaindazole series compound. It is used in inflammatory and metabolic research. Formula: C22H18FN5O3S.
|
| Molecular Formula |
C22H18FN5O3S
|
|---|---|
| Molecular Weight |
451.473426342011
|
| Exact Mass |
451.111
|
| CAS # |
1295298-26-8
|
| PubChem CID |
52916803
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
32
|
| Complexity |
809
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C)(C1C=C(C=CN=1)C1(CC1)NC(C1C=NC=C2C=1C=NN2C1C=CC(=CC=1)F)=O)(=O)=O
|
| InChi Key |
PXQATVYJKMMHAU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H18FN5O3S/c1-32(30,31)20-10-14(6-9-25-20)22(7-8-22)27-21(29)18-11-24-13-19-17(18)12-26-28(19)16-4-2-15(23)3-5-16/h2-6,9-13H,7-8H2,1H3,(H,27,29)
|
| Chemical Name |
1-(4-Fluorophenyl)-N-(1-(2-(methylsulfonyl)pyridin-4-yl)cyclopropyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxamide
|
| Synonyms |
BI639667 BI-639667 BI 639667
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10 mg/mL (~22.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (2.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (2.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (2.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2150 mL | 11.0749 mL | 22.1499 mL | |
| 5 mM | 0.4430 mL | 2.2150 mL | 4.4300 mL | |
| 10 mM | 0.2215 mL | 1.1075 mL | 2.2150 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT02133482
Conditions:HealthyProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
